Hospital General Universitario De Castellon

The urology department at Hospital General Universitario De Castellon is conducting studies on high‑risk localized or locally advanced prostate cancer, aiming to improve surgical outcomes and long‑term disease control.

• Combination therapy with apalutamide and androgen deprivation therapy
• Use of conventional and PSMA PET imaging to guide treatment
• Focus on pathological complete response and metastasis‑free survival

With 23 investigators involved, the site is evaluating whether adding apalutamide to standard therapy can raise cure rates while monitoring safety.

A trial at the same facility explores the effect of switching patients with narcolepsy from high‑sodium oxybate to the newer formulation XYWAV, with particular attention to 24‑hour ambulatory blood pressure.

• Blood pressure monitoring after medication switch
• Assessment of daytime sleepiness and nighttime sleep quality
• Evaluation of safety and tolerability of reduced‑sodium therapy

The study involves a multidisciplinary team and seeks to demonstrate that the new treatment can maintain symptom control while lowering cardiovascular risk.